“The pharmaceutical pathway and the natural medicine pathway are not competing rivers. They are tributaries of the same watershed.”
By Shannon Hughes, Elemental Psychedelics via Colorado Newsline
Two signatures, 48 hours apart, just changed how psychedelic medicine arrives in America.
On April 18, President Donald Trump signed an executive order accelerating federal review of psychedelic drugs for serious mental illness. Within days, the Food and Drug Administration (FDA) awarded three commissioner’s national priority vouchers—to Compass Pathways for psilocybin-assisted therapy in treatment-resistant depression, Usona Institute for psilocybin in major depressive disorder, and Otsuka for methylone (a relative of MDMA) in PTSD. These vouchers may compress what is typically a 10-to-12-month FDA review down to as little as one or two months.
On April 20, with far less fanfare, Gov. Jared Polis (D) signed Colorado’s Senate Bill 26-31. The bill specifies that the moment the Drug Enforcement Administration (DEA) reschedules an FDA-approved Schedule I drug, Colorado’s law follows automatically. Pharmaceutical psilocybin will be legal to dispense in Colorado the instant federal approval lands.
I’m hopeful about this. Patients with treatment-resistant depression have been waiting a long time. So have veterans with PTSD. So have practitioners who have spent years preparing to do
Read full article on Marijuana Moment
